Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.

Expert opinion on drug safety - 1 Mar 2015

Dikopf Alana, Wood Kevin, Salgia Ravi

Abstract excerpt

INTRODUCTION: In the past decade, the treatment of NSCLC has been revolutionized by the discovery of key oncogenic driver mutations and the therapies that specifically target these mutations. Crizotinib has been shown to be an inhibitor of MET, anaplastic lymphoma kinase (ALK) and ROS1 receptor tyrosine kinases, and is FDA approved for ALK inhibition. Crizotinib is effective in NSCLC that harbors ALK...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Crizotinib
Share to Drug Interactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Pyrazoles

Share to Pyridines

Share to Quality of Life

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 25659177
DOI: 10.1517/14740338.2015.1007040

Genes

ALK
MET
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.PMID 25659177Read ↗

Management of NSCLC: focus on crizotinib.Semantic proximity Read ↗

Crizotinib: an anaplastic lymphoma kinase inhibitor.Semantic proximity Read ↗

Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.Semantic proximity Read ↗

Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.Semantic proximity Read ↗

[Clinical research of crizotinib in advanced non-small cell lung cancer].Semantic proximity Read ↗

Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.Semantic proximity Read ↗

Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.Semantic proximity Read ↗

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisSemantic proximity Read ↗

Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.Semantic proximity Read ↗

Pharmacokinetics of crizotinib in NSCLC patients.Semantic proximity Read ↗

Efficacy and Safety of Ensartinib in the Treatment of Non-Small Cell Lung Cancer: A Systematic Review of Clinical TrialsSemantic proximity Read ↗

ALK in lung cancer: past, present, and future.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.